• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Clinical Outcomes of Plavix and Generic Clopidogrel for Patients Hospitalized With an Acute Coronary Syndrome Original Articles
Conclusions: Generic clopidogrel was noninferior to Plavix with respect to the composite end point of death and recurrent hospitalization for ACS at 1 year among adults >65 years after an ACS hospitalization. Our findings support generic clopidogrel in ACS, which could lead to substantial healthcare cost savings.
Source: Circulation: Cardiovascular Quality and Outcomes - March 13, 2018 Category: Cardiology Authors: Ko, D. T., Krumholz, H. M., Tu, J. V., Austin, P. C., Stukel, T. A., Koh, M., Chong, A., de Melo, J. F., Jackevicius, C. A. Tags: Health Services, Mortality/Survival Original Articles Source Type: research

Direct healthcare costs and cost-effectiveness of acute coronary syndromes secondary prevention with ticagrelor compared to clopidogrel - economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
CONCLUSIONS: In lifelong time horizon, which should be used in case of comparison of technologies with different impact on mortality, cost-effectiveness evaluation resulted in more favourable economic outcomes for ticagrelor than for generic clopidogrel with the cost per QALY well below recommended willingness to pay (WTP) threshold in Poland (24 965 PLN vs. 111 381 PLN). PMID: 24846362 [PubMed - as supplied by publisher]
Source: Polish Heart Journal - May 20, 2014 Category: Cardiology Authors: Pawęska J, Macioch T, Perkowski P, Budaj A, Niewada M Tags: Kardiol Pol Source Type: research

Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective.
CONCLUSION: Based on PLATO trial data, one-year treatment with ticagrelor versus generic clopidogrel in patients with ACS, relative to WHO reference standards, is cost-effective from a Singapore public healthcare perspective. PMID: 23546032 [PubMed - in process]
Source: Singapore Medical Journal - March 1, 2013 Category: Journals (General) Authors: Chin CT, Mellstrom C, Chua TS, Matchar DB Tags: Singapore Med J Source Type: research